Journal ArticleDOI
Standardizing training for Pressurized Intraperitoneal Aerosol Chemotherapy.
Mohammad Alyami,Olivia Sgarbura,Vladimir M. Khomyakov,Philipp Horvath,Giuseppe Vizzielli,Jimmy Bok Yan So,Juan José Torrent,Xavier Delgadillo,David C. Martin,Wim Ceelen,Marc A. Reymond,Marc Pocard,Martin Hübner +12 more
TLDR
An international panel of PIPAC experts created by means of a consensus meeting a structured 2-day training course including essential theoretical content and practical exercises enabling participants to safely implement PIPac.Abstract:
Background PIPAC is a novel mode of intraperitoneal drug delivery for patients with peritoneal cancer (PC). PIPAC is a safe treatment with promising oncological results. Therefore, a structured training program is needed to maintain high standards and to guarantee safe implementation. Methods An international panel of PIPAC experts created by means of a consensus meeting a structured 2-day training course including essential theoretical content and practical exercises. For every module, learning objectives were defined and structured presentations were elaborated. This structured PIPAC training program was then tested in five courses. Results The panel consisted of 12 experts from 11 different centres totalling a cumulative experience of 23 PIPAC courses and 1880 PIPAC procedures. The final program was approved by all members of the panel and includes 12 theoretical units (45 min each) and 6 practical units including dry-lab and live surgeries. The panel finalized and approved 21 structured presentations including the latest evidence on PIPAC and covering all mandatory topics. These were organized in 8 modules with clear learning objectives to be tested by 12 multiple-choice questions. Lastly, a structured quantifiable (Likert scale 1–5) course evaluation was created. The new course was successfully tested in five courses with 85 participants. Mean overall satisfaction with the content was rated at 4.79 (±0.5) with at 4.71 (±0.5) and at 4.61 (±0.7), respectively for course length and the balance between theory and practice. Conclusions The proposed PIPAC training program contains essential theoretical background and practical training enabling the participants to safely implement PIPAC.read more
Citations
More filters
Journal ArticleDOI
Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
Olivia Sgarbura,Laurent Villeneuve,Mohammad Alyami,Naoual Bakrin,Juan José Torrent,Clarisse Eveno,Martin Hübner,Julio Abba,Adnane Afifi,Michael Bau Mortensen,G. Bharath,Aditi Bhatt,Jimmy Bok Yan So,Andreas Brandl,Wim Ceelen,Delia Cortes-Guiral,Thomas Courvoiser,Julien Coget,Ignace H. J. T. de Hingh,Jean-Baptiste Delhorme,Suryanarayana S.V. Deo,Andrea Di Giorgio,Frédéric Dumont,Cecilia Escayola,Anne-Cécile Ezanno,Johan Gagnière,Julio Galindo,Torben Glatz,Tarkan Jäger,Maximilian Jarra,Ninad Katdare,Vahan Kepenekian,Vladimir M. Khomyakov,Konstantinos Kothonidis,Nathalie Laplace,Vincent Lavoué,Kuno Lehmann,Craig Lynch,Sanket Mehta,Bogdan Moldovan,Aviram Nissan,Maciej Nowacki,David Orry,Gloria Ortega Pérez,Urs G. Pabst,Brice Paquette,Marius Paškonis,Pompiliu Piso,Marc Pocard,Beate Rau,Marc A. Reymond,Frédéric Ris,M. Robella,José Silvestre-Rodriguez,Shivendra Singh,S.P. Somashekhar,Claudio Soravia,Isabelle Sourrouille,Abelkader Taibi,Clemens B. Tempfer,Jared Torkington,Giuseppe Vizzielli,Wouter Willaert +62 more
TL;DR: Homogeneous treatment standards of new techniques are important to guarantee safe implementation and practice but also to allow comparison between cohorts and multi-center analysis of merged data including registries.
Journal ArticleDOI
Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).
Koen P. Rovers,Emma C. E. Wassenaar,Robin J. Lurvink,Geert-Jan Creemers,Jacobus W. A. Burger,Maartje Los,Clément J. Huysentruyt,Gesina van Lijnschoten,Joost Nederend,Max J. Lahaye,Maarten J. Deenen,Marinus J. Wiezer,Simon W. Nienhuijs,Djamila Boerma,Ignace H. J. T. de Hingh +14 more
TL;DR: In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common, and the clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined.
Posted ContentDOI
Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin.
Fatah Tidadini,Julio Abba,Jean-Louis Quesada,Magalie Baudrant,Aline Bonne,Alison Foote,Jean-Luc Faucheron,Olivier Glehen,Laurent Villeneuve,Catherine Arvieux +9 more
TL;DR: The overall survival at 6 months after the diagnosis of carcinomatosis was significantly better for PIPAC_CHEM patients and this difference appears to continue until at least 18 months.
Journal ArticleDOI
Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Olivia Sgarbura,Clarisse Eveno,Mohammad Alyami,N. Bakrin,Delia Cortes Guiral,Wim Ceelen,Xavier Delgadillo,Thanh H. Dellinger,A. Di Giorgio,Amaniel Kefleyesus,Vladimir Khomiakov,Michael Bau Mortensen,Jamie Murphy,Marc Pocard,Marc A. Reymond,M. Robella,Koen P. Rovers,Jimmy Bok Yan So,S. P. Somashekhar,Clemens B. Tempfer,Kurt Van der Speeten,Laurent Villeneuve,Wei Peng Yong,Martin Hübner +23 more
TL;DR: The current consensus on current PIPAC treatment protocols should help to limit heterogeneity of treatment protocols but underlines the utmost importance of further research.
Journal ArticleDOI
PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.
Mustafa Raoof,Gautam Malhotra,Adrian Kohut,Michael P. O'Leary,Paul Frankel,Thuy B. Tran,Marwan Fakih,Joseph Chao,Dean Lim,Yanghee Woo,Isaac Benjamin Paz,Michael Lew,Mihaela C. Cristea,Lorna Rodriguez-Rodriguez,Yuman Fong,Andrew M. Blakely,Richard L. Whelan,Marc A. Reymond,Amit Merchea,Thanh H. Dellinger +19 more
TL;DR: In this article, the authors present the design and implementation of the first phase 1 trial to evaluate the safety and efficacy of PIPAC in the United States, which is an ongoing prospective phase 1 clinical trial for patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with metastases.
References
More filters
Journal ArticleDOI
No surgical innovation without evaluation: the IDEAL recommendations.
Peter McCulloch,Douglas G. Altman,W Bruce Campbell,David R. Flum,Paul Glasziou,John C. Marshall,Jon Nicholl +6 more
TL;DR: Recommendations for the assessment of surgery based on a five-stage description of the surgical development process are proposed and the widespread use of prospective databases and registries are encouraged.
Journal ArticleDOI
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.
Wiebke Solass,Reinhold Kerb,Thomas E. Mürdter,Urs Giger-Pabst,Dirk Strumberg,Clemens B. Tempfer,Jürgen Zieren,Matthias Schwab,Marc A. Reymond +8 more
TL;DR: PIPAC shows superior pharmacological properties with high local concentration and low systemic exposure, and can induce regression of PC in chemoresistant tumors, using 10 % of a usual systemic dose.
Journal ArticleDOI
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Mohammad Alyami,Martin Hübner,Fabian Grass,Fabian Grass,Naoual Bakrin,Laurent Villeneuve,Nathalie Laplace,Guillaume Passot,Olivier Glehen,Vahan Kepenekian +9 more
TL;DR: From the findings, PIPAC has been shown to be feasible and safe and can be considered as a treatment option for refractory, isolated peritoneal metastasis of various origins, however, its use in further indications needs to be validated by prospective studies.
Journal ArticleDOI
Description of a novel approach for intraperitoneal drug delivery and the related device
Wiebke Solaß,Alexander Hetzel,Giorgi Nadiradze,Emil Sagynaliev,Marc A. Reymond,Marc A. Reymond +5 more
TL;DR: This device and the related approach significantly improve both distribution and penetration of a test substance into the peritoneal cavity in a large animal model, which might be a significant progress in treating intraperitoneal disease, in particularPeritoneal carcinomatosis.
Journal ArticleDOI
Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States
Kiran K. Turaga,Edward A. Levine,Robert M. Barone,Robert P. Sticca,Nicholas J. Petrelli,Laura A. Lambert,Garrett M. Nash,Michael A. Morse,R. Adbel-Misih,H.R. Alexander,F. Attiyeh,David L. Bartlett,A. Bastidas,T. Blazer,Quyen D. Chu,K. Y. Chung,L. Dominguez-Parra,N. J. Espat,Jason M. Foster,Keith Fournier,Reynaldo Garcia,Michael D. Goodman,Nader Hanna,Lawrence E. Harrison,Richard A. Hoefer,Matthew P. Holtzman,John M. Kane,Daniel M. Labow,Benjamin D.L. Li,Andrew M. Lowy,Paul F. Mansfield,E. Ong,Colette R. Pameijer,James F. Pingpank,M. Quinones,Richard E. Royal,George I. Salti,Armando Sardi,Perry Shen,Joseph J. Skitzki,J. Spellman,John H. Stewart,Jesus Esquivel +42 more
TL;DR: This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field and studies directed at maximizing the efficacy of each of the key elements will need to follow.